A Simplified, Noninvasive Stool DNA Test for Colorectal Cancer Detection

Itzkowitz, Steven H.; Brand, Randall E.; Jandorf, Lina; Durkee, Kris; Millholland, John M.; Rabeneck, Linda; Schroy, Paul C.; Sontag, Stephen J.; Johnson, David A.; Markowitz, Sanford D.; Paszat, Lawrence; Berger, Barry M.

doi:10.1111/j.1572-0241.2008.02088.x

Cited by 147 publications

(110 citation statements)

References 26 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Since then, many studies have been devoted to vimentin methylation. Follow-up studies have obtained similar results and thus have reinforced the utility of vimentin as a standalone biomarker [47,54,55,59,61] . This has led to the commercialization of a single-gene stool kit for CRC detection based on vimentin methylation.…”

Section: Biomarkers Of Dna Methylation In Bloodsupporting

confidence: 54%

Advances in epigenetic biomarker research in colorectal cancer

Kuang

2014

WJG

View full text Add to dashboard Cite

Colorectal cancer (CRC) causes approximately 600000 deaths annually and is the third leading cause of cancer mortality worldwide. Despite significant advancements in treatment options, CRC patient survival is still poor owing to a lack of effective tools for early diagnosis and a limited capacity for optimal therapeutic decision making. Since there exists a need to find new biomarkers to improve diagnosis of CRC, the research on epigenetic biomarkers for molecular diagnostics encourages the translation of this field from the bench to clinical practice. Epigenetic alterations are thought to hold great promise as tumor biomarkers. In this review, we will primarily focus on recent advances in the study of epigenetic biomarkers for colorectal cancer and discuss epigenetic biomarkers, including DNA methylation, microRNA expression and histone modification, in cancer tissue, stool, plasma, serum, cell lines and xenografts. These studies have improved the chances that epigenetic biomarkers will find a place in the clinical practices of screening, early diagnosis, prognosis, therapy choice and recurrence surveillance for CRC patients. However, these studies have typically been small in size, and evaluation at a larger scale of well-controlled randomized clinical trials is the next step that is necessary to increase the quality of epigenetic biomarkers and ensure their widespread clinical use.

show abstract

Section: Biomarkers Of Dna Methylation In Bloodsupporting

confidence: 54%

Advances in epigenetic biomarker research in colorectal cancer

Kuang

2014

WJG

View full text Add to dashboard Cite

show abstract

“…Analysis includes numerous different technologies such as real-time PCR, single-base exten sion, variation scanning technology and automated sequencing (31)(32)(33)(34). Interpretation of results must therefore be performed individually for each technique rather than on a single platform as with the RanplexCRC Array panel.…”

Section: Discussionmentioning

confidence: 99%

“…Several faecal DNA tests are also currently available on the market (31)(32)(33)(34)(35) and most are based on the detection of multiple molecular markers for CRC including point mutations within K-ras, BRAF, TP53 and APC. Analysis includes numerous different technologies such as real-time PCR, single-base exten sion, variation scanning technology and automated sequencing (31)(32)(33)(34).…”

Section: Discussionmentioning

confidence: 99%

Simultaneous Detection of Colorectal Cancer Mutations in Stool Samples with Biochip Arrays

Murray¹,

Latten²,

Cartwright³

et al. 2009

Journal of Medical Biochemistry

View full text Add to dashboard Cite

Simultaneous Detection of Colorectal Cancer Mutations in Stool Samples with Biochip ArraysColorectal cancer (CRC) is the second main cause of cancer-related death in the Western world and like many other tumours is curable if detected at an early stage. Current detection options include faecal occult blood testing and invasive direct visualisation techniques such as flexible sigmoidoscopy, colonoscopy and barium enema. The availability of a more simple, non-invasive test that detects tumour specific products with optimal analytical performance might overcome barriers among patients who are not willing to undergo more sensitive but invasive tests. One such emerging technology, which has shown promise in recent years, is the analysis of DNA alterations exfoliated from tumour cells into stool. Here we report an analytical platform for non-invasive detection of 28 common mutations within CRC-related genesAPC, TP53, K-rasandBRAFin stool samples based on biochip array technology and applied to the semi-automated Evidence Investigator analyser. Mutation detection was possible in 1000-fold excess of wildtype DNA and analysis of 10 CRC-positive patient samples showed presence of targeted mutations with equivalent mutations also identified by an alternative method. This application represents an excellent tool for the multiplex detection of CRC-specific mutations using a single platform.

show abstract

“…This assay is currently commercially available in the United States as the ColoGuard assay (LabCorp), and reports a sensitivity of 83% and a specificity of 82%. [89,90] Outside of the United States, in Europe and the Middle East there is now an additional non-invasive test for early detection of colorectal cancer by assessing the methylation status of SEPT9. This assay is currently commercially available as Epi proColon (Epigenomics AG).…”

Section: Epigenomics and Epigeneticsmentioning

confidence: 99%